1. Academic Validation
  2. Anti-inflammatory Activity of Absinthin and Derivatives in Human Bronchoepithelial Cells

Anti-inflammatory Activity of Absinthin and Derivatives in Human Bronchoepithelial Cells

  • J Nat Prod. 2020 Jun 26;83(6):1740-1750. doi: 10.1021/acs.jnatprod.9b00685.
Maria Talmon 1 Lorenza Bosso 2 Martina Quaregna 1 Annalisa Lopatriello 3 Silvia Rossi 1 Daniele Gavioli 1 Patrizia Marotta 2 Diego Caprioglio 2 Renzo Boldorini 1 Riccardo Miggiano 2 Luigia G Fresu 1 Federica Pollastro 2
Affiliations

Affiliations

  • 1 Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Via Solaroli 17, 28100 Novara, Italy.
  • 2 Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.
  • 3 Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Napoli, Italy.
Abstract

Bitter taste receptors (hTAS2R) are expressed ectopically in various tissues, raising the possibility of a pharmacological exploitation. This seems of particular relevance in airways, since hTAS2Rs are involved in the protection of the aerial tissues from infections and in bronchodilation. The bis-guaianolide absinthin (1), one of the most bitter compounds known, targets the hTAS2R46 bitter receptor. Absinthin (1), an unstable compound, readily turns into anabsinthin (2) with substantial retention of the bitter properties, and this compound was used as a starting material to explore the chemical space around the bis-guaianolide bitter pharmacophore. Capitalizing on the chemoselective opening of the allylic lactone ring, the esters 3 and 4, and the nor-azide 6 were prepared and assayed on human bronchoepithelial (BEAS-2B) cells expressing hTAS2R46. Anti-inflammatory activity was evaluated by measuring the expression of MUC5AC, iNOS, and cytokines, as well as the production of superoxide anion, qualifying the methyl ester 3 as the best candidate for additional studies.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-N0742
    hTAS2R46 Agonist